Streetbeat News

Stock Prices

HD

M

TGT

TJX

WMT

Target Corporation reported an unexpected earnings beat for Q3 with revenue of $25.4 billion, surpassing estimates despite a YoY sales decline and a 5% drop in comparable sales. Digital sales fell 6% YoY, but net income rose 36% to $971 million. The earnings beat was attributed to strong sales in women's fall fashion apparel, jewelry, and a new kitchenware brand. However, Target's CFO warned of a challenging holiday quarter with expected mid-single-digit declines in comparable sales and adjusted EPS between $1.90 and $2.60. Walmart, which reports later in the week, did not hire additional holiday staff, suggesting a softer holiday season. Home Depot, Macy's, and TJX Companies are also set to report earnings this week.

Portfolio Pulse from Upwallstreet

November 15, 2023 | 5:04 pm

SLDB

Shares of Solid Biosciences Inc. (NASDAQ:SLDB) are rising after the FDA cleared its IND application for SGT-003, a gene therapy candidate for Duchenne muscular dystrophy. The company's CEO expressed optimism about the therapy's potential. The stock is trading on high volume, with over 10.25 million shares traded, surpassing the 100-day average of under 40 thousand shares. Last week, the company reported Q3 financial results with losses of $1.05 per share, better than the expected $1.19 per share and an improvement from the previous year's $2.71 per share loss.

Portfolio Pulse from Erica Kollmann

November 15, 2023 | 5:01 pm

ELTK

Eltek (NASDAQ:ELTK) is expected to release its quarterly earnings report on Thursday, 2023-11-16, with analysts estimating an EPS of $0.31. Investors are looking for an earnings beat and positive guidance for the next quarter. Eltek's stock performance has been strong, with shares up 183.92% over the last 52 weeks, trading at $11.61 as of November 14. Past earnings have resulted in varied share price changes on the following day.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:01 pm

VSTM

Verastem (NASDAQ:VSTM) has received 4 bullish analyst ratings in the last quarter, with no neutral or bearish ratings. The average 12-month price target among these analysts is $28.00, with a high of $36.00 and a low of $21.00. This target represents a 6.67% decrease from the previous target of $30.00. Analyst ratings are opinions on stock performance based on various analyses and are updated typically once per quarter.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:01 pm

VJET

voxeljet (NASDAQ:VJET) is expected to release its quarterly earnings report on Thursday, 2023-11-16, with analysts predicting an EPS of $-0.48. Investors are looking for an earnings beat and positive guidance for future growth. Historically, voxeljet's stock price has been volatile post-earnings, with a significant drop of 24.34% after beating EPS last quarter. The stock is currently trading at $1.32, down 59.55% over the last year, indicating negative sentiment among long-term shareholders ahead of the earnings release.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:01 pm

BMY

Bristol-Myers Squibb (NYSE:BMY) has received mixed analyst ratings in the last quarter with 3 bullish, 2 somewhat bullish, 8 indifferent, and 2 somewhat bearish ratings. The average price target is $63.13, representing an upside from the current price of $50.555. This target has decreased by 4.51% from the previous target of $66.11. Analysts rate stocks based on research and provide guidance to investors, though their predictions are opinions and subject to human error.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

CPRT

Copart (NASDAQ:CPRT) is scheduled to release its quarterly earnings report on Thursday, 2023-11-16, with analysts expecting an EPS of $0.32. Investors are looking for an earnings beat and positive guidance for the next quarter. Copart's stock performance has been positive over the last 52 weeks, with shares up 55.13%, trading at $49.69 as of November 14. Past earnings have shown mixed reactions in stock price post-announcement.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

CASI

HC Wainwright & Co. has reaffirmed its Buy rating on CASI Pharmaceuticals (NASDAQ:CASI), increasing the price target from $10.00 to $12.00. CASI's stock has risen 1.33% to $4.56 in the last 24 hours. The new price target suggests a potential upside of 163.16%. CASI focuses on commercializing therapeutics for leukemias, lymphomas, and multiple myeloma, with EVOMELA being a key revenue driver.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

ALPN

Alpine Immune Sciences (NASDAQ:ALPN) received 10 analyst ratings in the last quarter, with an average price target of $21.6, representing significant upside from the current price of $12.4. The consensus shows 3 bullish, 7 somewhat bullish, and no bearish ratings. The average price target has increased by 25.22% from the previous target of $17.25.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

CABA

Cantor Fitzgerald has reaffirmed its Overweight rating on Cabaletta Bio (NASDAQ:CABA) and increased its price target from $40.00 to $50.00. Cabaletta Bio's shares have risen 1.66% to $17.76. The new price target suggests a potential upside of 181.53%. Cabaletta Bio is a clinical-stage biotech company developing engineered T cell therapies for B cell-mediated autoimmune diseases.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm